Aclaris Reports Q3 2026 Results, $204.6M in Cash and Securities

Aclaris reported Q3 2026 revenue of $1.5M and a net loss of $18.5M, down from $3.3M and $14.6M respectively a year earlier. Cash reserves totaled $204.6M, with runway extended to mid-2029. Positive Phase 1b results for ATI-052 in atopic dermatitis and asthma were announced. ACRS

Original reporting
Published Nov 5, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aclaris Reports Q3 2026 Results, $204.6M in Cash and Securities — source image
Decision brief

The 30-second read

$ACRSBearishHigh
01

Why it matters

The earnings miss is likely to weigh on the stock, but the positive Phase 1b data for ATI-052 could attract interest from investors seeking pipeline catalysts.

02

Market read

The report provides fresh financial and clinical data that can drive short‑term price movement for ACRS.

03

What to watch

The $204.6M cash runway through 2029 may give the company time to monetize its pipeline, mitigating short‑term loss concerns.

Relevance 8/10Novelty 8/10Timing: after market close

Background

Aclaris Therapeutics (ACRS) is a clinical‑stage biotech focused on inflammatory diseases. The Q3 2026 filing includes both financial results and early trial data.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Aclaris Therapeutics reported Q3 2026 results with a $1.5M revenue decline, $18.5M net loss and positive Phase 1b data for ATI-052.

Expected impact

likely pressure as the market prices in the revenue decline and larger loss despite encouraging trial results

Evidence & confidence

The earnings numbers are materially worse than a year ago, which typically drives the stock lower, while the trial data is a positive catalyst but may not offset the financial disappointment.

Market effects

Biotech sector may see mixed sentiment as trial data is positive but earnings miss highlights cash burn concerns.

US biotech investors may adjust exposure to early‑stage companies with high cash burn.

Limited to investors tracking small‑cap biotech earnings and pipeline updates.

Counterpoint

The strong Phase 1b results could signal a future upside if the company secures further funding and advances to Phase 2b.

Key entities

  • Aclaris Therapeutics, Inc.

    Clinical‑stage biotech reporting Q3 2026 results.

Related articles

$ACRSMed

Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial

Aclaris Therapeutics reported that bosakitug failed to meet primary and secondary endpoints in its Phase 2 atopic dermatitis trial but was well tolerated. The company advanced its clinical pipeline, initiating a Phase 2b trial for modzatinib in lichen planus and planning Phase 1 and 2b trials for ATI-9494 and ATI-052, respectively, in 2027. According to the company, bosakitug showed target engagement and reduced immune-activation biomarkers.

$ACRSLowAI 8/10

Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score

$ACRSMedAI 8/10

Aclaris Reports Bosakitug Phase 2 Setback, Focuses To Other Pipeline Programs

Aclaris Therapeutics (ACRS) reported that its Phase 2 trial for bosakitug in treating atopic dermatitis did not meet primary or secondary endpoints. Despite this, the drug showed target engagement and was well tolerated. ACRS will focus on other pipeline programs, including modzatinib, ATI-9494, and ATI-052, with multiple milestones expected in 2027. The stock is down 14.29% in pre-market trading.

$ACRSMedAI 8/10

Aclaris Therapeutics (ACRS) Phase 2 Trial Misses All Endpoints

Aclaris Therapeutics (ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug for atopic dermatitis missed all primary and secondary endpoints. The drug was well tolerated, but the company will focus on other pipeline assets, with upcoming catalysts including an IND filing for ATI-9494 and Phase 2b trials for modzatinib and ATI-052.